Key statistics
On Friday, Ardelyx Inc (41X:STU) closed at 5.50, -20.87% below its 52-week high of 6.95, set on Jan 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.50 |
|---|---|
| High | 5.56 |
| Low | 5.37 |
| Bid | 5.52 |
| Offer | 5.55 |
| Previous close | 5.61 |
| Average volume | 585.71 |
|---|---|
| Shares outstanding | 245.25m |
| Free float | 237.05m |
| P/E (TTM) | -- |
| Market cap | 1.61bn USD |
| EPS (TTM) | -0.2576 USD |
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
- Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
- Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
- Ardelyx Receives New Patent for Tenapanor
- First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
- Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
- Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
- Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
- Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
- Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
More ▼
